Milestone Pharmaceuticals Inc. Common Shares
MISTStock
$1.24−5.80%52W
Market Cap$158.11M
P/E—
Div yield—
Beta0.97
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-45.26%
Price vs S&P 500 (4W)-0.37%
VGM Score31.04
Market Capitalization$158.11M
Earnings Surprise History
Q1 26-0.20est. 0.31
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.00
4.08
4.08
4.08
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
MISTMilestone Pharmaceuticals Inc. Common Shares | D | — | D | $1.24 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Milestone Pharmaceuticals is a biopharmaceutical company developing etripamil, a rapid-onset calcium channel blocker delivered as a nasal spray for cardiovascular conditions. The company is commercializing etripamil for paroxysmal supraventricular tachycardia (PSVT) treatment and has a Phase 2 clinical trial underway for atrial fibrillation with rapid ventricular rate (AFib-RVR).